Dyslipidemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Dyslipidemia is the imbalance of lipids such as cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein (HDL). According to the Frederickson phenotype, dyslipidemia is classified into five categories. Phenotype I is a chylomicron abnormality that results in triglycerides higher than the 99 percentiles. Phenotype IIa is characterised primarily by LDL cholesterol abnormalities, with total cholesterol concentrations greater than the 90th percentile and possible apolipoprotein B more significant than the 90 percentile. The phenotype IIb consists of abnormality in LDL and very low-density lipoprotein (VLDL) cholesterol. The most critical complication of dyslipidemia is cardiovascular disease. This can lead to sudden cardiac death, acute myocardial infarction, or stroke. Multiple studies have shown that statins and appropriate dyslipidemia treatment reduce the risk of all-cause mortality, cardiovascular events, and cardiovascular mortality significantly.
·
The prevalence of dyslipidemia increases with
age; an estimated 33.5% of United States adults older than 20 years of age had
high LDL-C levels, ~48.1% received treatment, and 33.2% had their LDL-C
controlled.
Thelansis’s “Dyslipidemia Market
Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report – 2021 To 2032" covers disease
overview, epidemiology, drug utilization, prescription share analysis,
competitive landscape, clinical practice, regulatory landscape, patient share,
market uptake, market forecast, and key market insights under the potential Dyslipidemia
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Dyslipidemia across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Dyslipidemia Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment